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Abstract
Objective: Dementia with Lewy bodies (DLB) is associated with the accumula-
tion of wild-type human a-synuclein (SYN) in neurons and with prominent
slowing of brain oscillations on electroencephalography (EEG). However, it
remains uncertain whether the EEG abnormalities are actually caused by SYN.
Methods: To determine whether SYN can cause neural network abnormalities,
we performed EEG recordings and analyzed the expression of neuronal activity-
dependent gene products in SYN transgenic mice. We also carried out compar-
ative analyses in humans with DLB. Results: We demonstrate that neuronal
expression of SYN in transgenic mice causes a left shift in spectral power that
closely resembles the EEG slowing observed in DLB patients. Surprisingly, SYN
mice also had seizures and showed molecular hippocampal alterations indicative
of aberrant network excitability, including calbindin depletion in the dentate
gyrus. In postmortem brain tissues from DLB patients, we found reduced levels
of calbindin mRNA in the dentate gyrus. Furthermore, nearly one quarter of
DLB patients showed myoclonus, a clinical sign of aberrant network excitability
that was associated with an earlier age of onset of cognitive impairments. In
SYN mice, partial suppression of epileptiform activity did not alter their shift
in spectral power. Furthermore, epileptiform activity in human amyloid precur-
sor protein transgenic mice was not associated with a left shift in spectral
power. Interpretation: We conclude that neuronal accumulation of SYN slows
brain oscillations and, in parallel, causes aberrant network excitability that can
escalate into seizure activity. The potential role of aberrant network excitability
in DLB merits further investigation.
Introduction
Dementia with Lewy bodies (DLB) belongs to a family of
common neurodegenerative diseases called synucle-
inopathies, which are pathologically characterized by the
mislocalization and aggregation of the small, presynaptic
protein a-synuclein (SYN). DLB, Parkinson’s disease (PD),
and Parkinson’s disease with dementia (PDD) are closely
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related synucleinopathies, but are distinguished by
differences in the relative onset of motor and cognitive
impairments and in the distribution of SYN pathology.1
While much is known about the motor impairments in PD,
very little is known about the mechanisms of cognitive
impairment and cortical network dysfunction in DLB and
PDD. DLB and PDD patients have dementia with visual
hallucinations, attentional fluctuations, and parkinsonism.1
These symptoms are associated with a prominent slowing
of cortical oscillations on electroencephalography (EEG),
resulting in a shift in spectral power from higher (alpha,
beta, gamma) to lower (delta, theta) frequency bands.2,3
However, it remains uncertain whether the neural network
and cognitive dysfunction in these conditions are actually
caused by SYN.
EEG slowing in neurodegenerative diseases is often
attributed to the loss of cholinergic neurons projecting to
the cortex. In some Alzheimer’s disease (AD) patients,
treatment with inhibitors of acetylcholinesterase, adminis-
tered to compensate for cholinergic denervation, can
improve frontal EEG activity and some cognitive func-
tions.4,5 DLB patients have a greater loss of cholinergic
neurons6 and show more EEG slowing, as well as greater
clinical improvement, with acetylcholinesterase inhibitor
treatment7 than AD patients.2,3 Although DLB and PDD
patients show loss of cholinergic projections in most cor-
tical areas,6,8 cholinergic treatment normalizes brain activ-
ity only in the frontal cortex, as measured by resting-state
fMRI,9 suggesting that different mechanisms contribute to
network dysfunction in other cortical regions. Defining
these mechanisms of neural network dysfunction may
lead to new therapeutic interventions for DLB patients.
Notably, neuronal overexpression of SYN impairs presy-
naptic release10,11 and causes behavioral deficits in SYN
transgenic mice,12,13 and pharmacologically decreasing
presynaptic release of neurotransmitters decreases the
power of high-frequency brain oscillations on EEG.14 These
findings raise the possibility that SYN causally contributes
to neural network dysfunction in DLB and PDD patients.
To test this hypothesis, we performed EEG recordings and
analyzed the expression of neuronal activity-dependent
gene products in SYN transgenic mice. We also carried out
comparative analyses in humans with DLB.
Subjects and Methods
Chart review and analysis of clinical data
We searched the electronic database of the UCSF Memory
and Aging Center for patients who were seen between
2007 and 2012, met McKeith criteria1 for DLB on their
latest evaluation during that period, and had a clinical
diagnosis of DLB (n = 178) (Fig. 1). Of these, 16 DLB
patients were removed because their records were incom-
plete. We searched the remaining patient records for
seizures, epilepsy, myoclonus, head trauma, and fluctua-
tions using the word stems “seiz-”, “spells”, “epil-”, “eeg”,
“myo-”, “head”, and “fluc-”. A seizure disorder (i.e., epi-
lepsy) was defined as two or more unprovoked seizures
or one unprovoked seizure with EEG evidence of epilepti-
form activity.15 We excluded patients who had a seizure
but did not meet the criteria for a seizure disorder
(n = 1) or had other seizure risk factors, including uri-
nary tract infection with a fever (n = 1), normal pressure
hydrocephalus with a shunt and fever (n = 1), stroke
(n = 1), and a frontal cavernous hemangioma (n = 1).
Among the remaining 157 DLB patients, 4 (2.5%)
patients met the criteria for a seizure disorder and 34
(21.7%) patients were noted to have myoclonus. All four
patients with a seizure disorder carried the clinical diag-
nosis of seizures and were on anti-epileptic medications.
In 12 (7.6%) patients without the diagnosis of a seizure
disorder, EEGs had been obtained for suspected seizures.
None of the patients with a seizure disorder, but one
patient with myoclonus, had a history of mild head
trauma with loss of consciousness for several minutes. A
mixed-effects linear model was fit to age of onset of
cognitive impairment with sex, education, handedness,
fluctuations, seizure disorder, and myoclonus as indepen-
dent variables. The presence versus absence of a clinical
history of fluctuations, seizure disorder, or myoclonus
was quantified using 1 or 0, respectively. Reported
P-values were derived from the mixed-effects linear model
including all variables. Significance was retained in a
mixed-effects linear model of age of onset of cognitive
impairment using only sex (P = 0.002) and myoclonus
(P = 0.008) as independent variables.
Incidence rates for myoclonus and a first unprovoked
seizure (FUS) were calculated separately using 6 person-
years per DLB patient in the study (Fig. 1). Fourteen
patients with myoclonus and one patient with FUS prior to
2007 were excluded from the respective incidence calcula-
tions. Two patients who were unaffected during the inci-
dence study period (2007–2012) developed myoclonus in
2013. There were 18 new cases of myoclonus and three new
cases of FUS in our population between 2007 and 2012. As
onset of myoclonus was not usually noted in the clinical
history, it was estimated using the first mention of myoclo-
nus in clinic notes after the initial evaluation. Both myoclo-
nus (median: +2 years relative to diagnosis, range 5 to
+9) and seizures (median: 1 year relative to diagnosis,
range 1 to +1) tended to begin near the diagnosis of
dementia. Therefore, the age of dementia diagnosis was
used to stratify the DLB population without myoclonus or
seizures. Relative rates and confidence intervals were
calculated according to published formulas.16
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Twelve DLB cases came to autopsy. The likelihood that
clinical dementia was caused by Lewy body pathology seen
on autopsy was estimated using McKeith criteria.1 The
presence of neocortical DLB was either directly stated by
the pathologist (n = 9) or inferred from the description of
Lewy body pathology (n = 2). The presence of AD pathol-
Figure 1. Workflow of the chart review analysis.
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ogy was based on autopsy summary statements and NIA-
Reagan criteria.17 Two cases had frequent plaques but
Braak stages below five and were unclassifiable by NIA-Rea-
gan criteria. To determine the relative contribution of AD
pathology to dementia in these cases, we classified them as
NIA-Reagan Intermediate (Braak stage 4) and NIA-Reagan
Low (Braak stage 0). All studies in human subjects were
approved by the Committee on Human Research of the
University of California, San Francisco. All human research
subjects provided written informed consent before partici-
pating in protocols from which data were derived and were
not required to re-consent for this analysis.
EEG recordings in human subjects
DLB patients and control subjects without clinical neuro-
logical disease were recruited specifically to assess EEG
changes in neurodegenerative disease. EEG recordings
were obtained using an international 10–20 electrode
placement. Participants were placed in the recumbent
position with eyes closed and resting-state EEG activity
was recorded for 50 min. One minute from the initial
20 min of recording, during which all subjects were
awake, was used for analysis. All human research subjects
had previously provided written informed consent to par-
ticipate in protocols from which data were derived and
were not required to re-consent for the above analysis.
Human tissues
Human postmortem brain samples (Table 1) were
obtained from the brain bank of the University of
California at San Diego (UCSD) and the New York Brain
Bank (NYBB) at Columbia University. The dentate gyrus
was isolated over dry ice from larger tissue blocks.
Calbindin mRNA levels, normalized to 18S RNA levels in
the dentate gyrus, were similar in the disease groups from
both brain banks (data not shown).
Mice and tissues
For most experiments in this study, we used mice express-
ing human wild-type a-synuclein (Thy1-SYN line 61,18
hereafter called SYN mice) or human amyloid precursor
protein (hAPP) with Swedish and Indiana mutations (pla-
telet-derived growth factor (PDGF) b-hAPP line J2019),
and mice lacking endogenous tau20 on a pure C57Bl/6J
background (Table S1). The data in Figure 6D–H (cohorts
J–K) were obtained in mice that were mostly C57Bl/6J with
some DBA2 background. EEG studies on SYN mice
revealed similar levels of epileptiform activity and spectral
alterations on both backgrounds (data not shown). For all
experiments involving SYN mice, only male mice were used
because the SYN transgene in line 61 is located on the X-
chromosome.13 To generate SYN mice on a Tau knockout
background, female SYN mice were bred to male mice lack-
ing endogenous tau. From the F1 generation, female SYN/
Tau+/ mice were bred to male Tau+/ mice to generate
the male SYN/Tau+/+ and SYN/Tau/ mice used in this
study. In all mouse cohorts, 40–100% of nontransgenic
(NTG) controls were littermates of transgenic mice, and
the remaining NTG controls were from the same SYN
breeding colony. Groups of different genotypes within each
cohort were age-matched. Mouse age did not significantly
affect SYN overexpression on any of the measures analyzed;
however, this study was not designed to evaluate age-re-
lated phenotypic changes. Food (Picolab Rodent Diet 20,
LabDiet, St. Louis, MO, USA) and water were given ad libi-
tum and mice were kept on a standard 12-h light/dark
cycle. Mice were housed in a specific pathogen—free facil-
ity and all procedures were done during daylight hours
unless otherwise specified. Mice used for immunohisto-
chemistry were deeply anesthetized with Avertin (2.5% w/v
in 2.5% tert-amyl alcohol/saline) and killed by transcardial
perfusion with saline. One hemibrain was post-fixed for
24–48 h in 4% paraformaldehyde in phosphate-buffered
saline (PBS) and the other hemibrain was frozen on dry ice.
Sections from PDGFb-SYN mice (line D18) and the tissue
used for Figure 4 were a gift from Dr. Eliezer Masliah
(Departments of Neuroscience and Pathology, University
of California, San Diego). The data in Figure 4 (cohort F)
were obtained from mouse tissue on a C57Bl/6 background
from Charles River with some DBA2 background, also
from Charles River. All experiments were approved by the
Institutional Animal Care and Use Committee of the
University of California, San Francisco.
EEG recordings in mice
Lightweight EEG plugs were constructed in-house by sol-
dering four Teflon-coated silver wires (0.125 mm diame-
ter) to a multichannel electrical connector. These plugs
Table 1. Human postmortem tissues.
Diagnosis (n)
Age
(mean  SD)
Sex
(M/F)
RNA integrity
number
(mean  SD)
No neurodegenerative
disease (3)
84  5.0 2/1 7.8  0.2
DLB with marked AD
pathology (6)
78  4.5 5/1 6.1  2.0
DLB with minimal AD
pathology (5)
77  5.4 4/1 5.3  0.6
AD (7) 79  2.9 2/5 6.5  1.3
DLB, Dementia with Lewy bodies; AD, Alzheimer’s disease.
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were surgically implanted into avertin-anesthetized mice,
placing the silver wire leads into the subdural space.
Reference leads were placed ~1 mm posterior and
1 mm mediolateral to bregma, and recording leads
~1 mm anterior and 2 mm mediolateral to lambda.
Mice were allowed to recover from surgery for at least
1 week before EEG recordings. EEG activity was recorded
for 24 h in freely moving mice using Harmonie 5.0b
software (Stellate Systems, Natus, Pleasanton, CA, USA),
with one of the rostral leads serving as the reference elec-
trode. For experiments shown in Figure 6B and C, pheno-
barbital sodium (0.5 mg/mL in sterile saline) was injected
i.p. after four or more hours of baseline recording. For
experiments shown in Figure 6I, donepezil hydrochloride
(0.1 mg/mL in sterile saline) was injected i.p. every morn-
ing for 14 days; recording began immediately after the
last injection.
Spectral analysis
For spectral analysis in humans, 60 sec artifact-free EEG
segments from the PZ electrode were selected manually.
The signal from the PZ electrode was recorded from the
parietal cortex and normalized to a calculated signal
representing the center of the brain. In two subjects (one
control and one DLB patient) who had no artifact-free
periods, a recording segment with minimal artifacts was
selected.
For spectral analysis in mice, 20–140 sec EEG segments
were selected during daytime resting behavior; the exact
segment length depended on the time mice displayed rest-
ing behavior. Resting behavior was defined as lack of
movement in the absence of EEG patterns suggestive of
sleep entry such as sinusoidal changes in EEG amplitudes
in the 5–15 Hz range. This approach minimizes the possi-
bility that the time points analyzed occurred during sleep.
Spectral analysis in phenobarbital- or donepezil-treated
mice was conducted during the period of spike reduction
or 3–4 h21 after the drug injection, respectively. EEG
recordings were evaluated by a reader blinded to the Tau
genotype. However, blinding to SYN genotype was not
possible because of the epileptiform activity associated
with this genotype.
Selected segments were converted into European Data
Format files and imported into LabChart 7 Pro (AD
Instruments, Colorado Springs, CO, USA) for spectral
analysis. A 60-Hz notch filter was applied to all cases in
which an electrical artifact was observed. Spectral power
was obtained by subjecting the recordings to a fast Fourier
transform (FFT) using a Hann cosine-bell window with
no overlap between windows. Using the EEG sampling
rate, we calculated the FFT size necessary for a resolution
of 0.5 Hz and selected the nearest higher FFT size avail-
able in LabChart. Human EEGs were recorded at a 600-
Hz sampling rate and FFT was performed with a 2048
point FFT size to obtain a resolution of 0.29 Hz. Mouse
EEGs were recorded at a 200-Hz sampling rate and FFT
was performed with a 512 point FFT size to obtain a reso-
lution of 0.39 Hz. Spectrogram text files were analyzed in
Excel by removing time points containing movement or
epileptiform activity and averaging the remaining 20–
60 sec of data. Average power for each frequency block
was then normalized to the total averaged power to obtain
relative spectral power. Relative power cumulative distri-
bution functions (CDF) were obtained using the integral
function in Prism (GraphPad Software, La Jolla, CA,
USA).
For Figure 2E, selected segments were exported as a
text file and spectral power was obtained using a custom-
written Matlab script and an FFT size of 1000 points to
obtain data at 5-sec intervals.22 Spectral frequency bands
were defined as follows: d = 0.5–4 Hz, h = 4–10 Hz,
a = 10–13 Hz, b = 13–20 Hz, and c = 20.1–99.9 Hz. The
EEG signal during resting behavior in Figure 2E was
analyzed over time in each frequency band using
a repeated measures mixed-model analysis with a Holm
P-value correction for multiple comparisons.
Analysis of epileptiform activity
Epileptiform activity in mice was detected with the Got-
man spike detector set to threshold 8 (Harmonie, Stel-
late). Events marked as epileptiform that coincided with
large or sudden movements, such as rapid turns, groom-
ing, digging, and eating, were removed as possible arti-
facts. Myoclonic jerks, defined as epileptiform activity
accompanied by sudden abnormal movements in an
otherwise motionless mouse, were not excluded. Baseline
epileptiform activity was quantified during 12–16 h of
EEG recordings (50% during light cycle, 50% during dark
cycle), excluding the first hour of recording and the first
half hour after the change in light condition. Drug effects
were assessed by comparing the extent of epileptiform
activity during the 2 h preceding and 2.5 h following the
injection, excluding from analysis the first half hour after
the injection.
Immunohistochemistry
Fixed hemibrains were stored at 4°C in PBS for 24 h and
then in 30% sucrose/PBS until they were sectioned at
30 lm on a microtome (Leica Microsystems Inc., Buffalo
Grove, IL, USA). Sections were stored at 20°C in a solu-
tion containing 30% glycerol, 30% ethylene glycol, and
40% PBS until staining. Primary antibodies were rabbit
anti-calbindin (1:50,000, Swant, Marly, Switzerland), rab-
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bit anti-NPY (neuropeptide Y) (1:8000, Immunostar,
Hudson, WI, USA) and rabbit anti-cfos (1:10,000, Ab-5,
EMD Millipore, Billerica, MA, USA). Primary antibody
binding was detected with biotinylated donkey anti-rabbit
(1:500, Jackson Immunoresearch, West Grove, PA, USA),
followed by avidin–biotin complex (Vector Laboratories,
Burlingame, CA, USA). Quantification was done as
described,23 except that optical density measurements of
calbindin immunoreactivity in the dentate gyrus was not
normalized to that in CA1, because calbindin was also
reduced in the latter region. Quantification of calbindin
levels for Figure 4 was performed as above except images
were captured with a BZ-9000 automated microscope sys-
tem (Keyence, Itasca, IL, USA) and optical density was
measured using elliptical regions of interest in Image J
software version 1.47 (http://imagej.nih.gov/ij). The
experimenter was blinded to mouse genotype.
Western blotting
Hippocampi were dissected from hemibrains over ice and
homogenized in ice-cold Pierce RIPA buffer containing
Complete protease inhibitor cocktail and phosphatase
inhibitor cocktails 2 and 3. The homogenates were
sonicated twice for 5 min at 40 A using an EpiSonic
Multi-Functional Bioprocessor (Epigentek, Farmingdale,
NY, USA). Proteins (20 lg/well) were separated on a 4–
12% NuPAGE Bis-Tris gel (Life Technologies, South San
Figure 2. DLB in humans and neuronal expression of wild-type
human SYN in transgenic mice cause a similar left shift in EEG
spectral power. (A and B) Brain oscillations in patients with DLB
(n = 6, solid line) and control subjects (n = 8, dashed line) were
recorded by high sampling frequency EEG/MEG. (A) Relative power (in
percent of total power) of brain oscillations of different frequencies
recorded by EEG over the parietal cortex (0–40 Hz zoom shown for
clarity). (B) The CDF of relative power was calculated from high
sampling frequency EEG recordings and revealed a shift to lower
frequencies in DLB patients (P < 0.0001 by Kolmogrov–Smirnov test).
(C–E) SYN mice (n = 14, solid line and black bars) and NTG
littermates (n = 9, dashed line and white bars) were analyzed by EEG
at 4–8 months of age. (C) Relative power (in percent of total power)
of brain oscillations of different frequencies recorded over the parietal
cortex (0–40 Hz zoom shown for clarity). (D) CDF of relative power
revealed a shift to lower frequencies in SYN mice (P < 0.0001 by
Kolmogrov–Smirnov test). (E) Relative power (in percent of total
power) of brain oscillations of different frequency bands. d = 0.5–
4 Hz, h = 4–10 Hz, a = 10–13 Hz, b = 13–20 Hz, c = 20.1–99.9 Hz.
(A–D) Black curves represent means and shadings 95% confidence
intervals. (E) *P < 0.05, **P < 0.01 versus NTG (repeated measures
mixed-effects model of relative power over time with Holm
correction). Values are means  SEM; some error bars are too small
to be visible. DLB, Dementia with Lewy bodies; SYN, a-synuclein; EEG,
electroencephalography; CDF, cumulative distribution function; NTG,
nontransgenic.
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 1017
M. Morris et al. Alpha-Synuclein Induced Network Dysfunction
Francisco, CA, USA) and transferred onto nitrocellulose
membranes for 9 min using iBlot (Life Technologies).
After blocking for 1 h in a solution of 5% bovine serum
albumin in Tris-buffered saline (BSA-TBS), membranes
were incubated overnight at either room temperature with
an antibody against phosphorylated SYN (1:500, Wako,
Richmond, VA, USA) or at 4°C with antibodies against
SYN (1:1000, Millipore) or a-tubulin (1:50,000, Sigma-
Aldrich, St. Louis, MO, USA). Antibodies were diluted in
BSA-TBS containing 0.1% Tween 20 (BSA-TBST). All
membranes were incubated for 1 h at room temperature
in a solution of IRDye 800CW-tagged or 680LT-tagged
donkey anti-rabbit or donkey anti-mouse secondary anti-
bodies (1:10,000, Li-Cor, Lincoln, Nebraska, USA) in
Odyssey blocking buffer with 0.2% Tween 20. Signals
were detected with an Odyssey CLx laser scanner (Li-Cor)
and quantified using Image Studio software v2.1.10 (Li-
Cor).
RNA isolation and RT-qPCR analysis
Frozen tissue (approximately half of the dissected dentate
gyrus) was homogenized for 20 sec in 500 lL of TRIzol
reagent at 20,000–21,000 rpm (Polytron homogenizer)
and incubated on ice for 5 min. Samples were then mixed
with 100 lL chloroform, incubated briefly on ice, and
centrifuged in heavy phase lock gel tubes at 12,000g and
4°C for 5 min. The supernatant was mixed with 250 lL
isopropanol, incubated for 10 min at room temperature,
and centrifuged at 12,000g and 4°C for 10 min. The pellet
was re-suspended in 75% ethanol and briefly spun at
7500g at 4°C. The resulting pellet was then dissolved in
100 lL of water and incubated at 56°C for 10 min,
followed by addition of 350 lL RLT buffer from the
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and
250 lL ethanol. The RNA was further purified using the
RNeasy Mini Kit following the “On-column DNase diges-
tion” protocol using 30 lL water for final elution. RNA
concentration was measured by Nanodrop (ND-1000;
Thermo Fisher Scientific, Waltham, MA, USA). RNA
integrity was determined on a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA) according to the
manufacturer’s instructions. All RNA samples were
diluted to the same concentration and reverse transcribed
with oligo-dTs and random hexamers according to the
manufacturer’s instructions (TaqMan Reverse Transcrip-
tion Reagents; Thermo Fisher Scientific). Negative con-
trols were generated by combining several samples and
running RT-qPCR without reverse transcriptase. qPCR
was carried out with SYBR green (SYBR green PCR Mas-
ter Mix, Applied Biosystems) on a 7900HT Fast Real-
Time PCR System (Applied Biosystems). To ensure that
RNA quality was sufficient for RT-qPCR measurements,
only samples with an RNA integrity number greater than
4.0 were analyzed. RNA integrity was not significantly dif-
ferent between groups by one-way analysis of variance
(ANOVA) (data not shown). The experimenter was
blinded to the pathological diagnosis of human cases.
Chemicals
The following chemicals were used: avertin prepared from
99% pure tribromoethanol (A18706; Alfa Aesar, Ward
Hill, MA, USA) and tert-amyl alcohol (Sigma-Aldrich),
phenobarbital sodium (5-ethyl-5-phenyl-2,4,6-trioxohex-
ahydropyrimidine sodium salt, P5178; Sigma-Aldrich),
paraformaldehyde diluted from 32% solution (Electron
Microscopy Sciences, Hatfield, PA, USA), TRIzol reagent
(Life Technologies), chloroform (Sigma-Aldrich), glycerol
(Fisher Scientific, Pittsburgh, PA, USA), ethylene glycol
(Fisher Scientific), PBS diluted from 10X stock solution
(Mediatech, Inc., Manassas, VA, USA), RIPA buffer
(Thermo Fisher Scientific), Complete protease inhibitor
cocktail (Roche, Indianapolis, IN, USA), phosphatase
inhibitor cocktails 2 and 3 (Sigma-Aldrich), BSA (Sigma-
Aldrich), TBS diluted from 10X stock solution (Fisher
Scientific), Odyssey blocking buffer (Li-Cor), Tween-20
(Bio-Rad, Hercules, CA, USA), and donepezil hydrochlo-
ride (4385; Tocris, Minneapolis, MN, USA).
Statistics
Prism (GraphPad) was used to analyze and graph all data
unless otherwise specified. CDF were generated using the
integral function in Prism. Repeated-measures mixed-
effects model analysis in Stata (StataCorp LP, College Sta-
tion, TX, USA) was used to analyze the frequency band
graph with multiple time points (Fig. 2E). Correlations of
SYN levels with calbindin were done using linear regres-
sion. A mixed-effects linear model in Stata was fit to the
age of onset of cognitive impairment of DLB patients, as
detailed in the chart review section above. Incidence rate
ratios and 95% confidence intervals were calculated as
described.16 Findings were considered significant at
P < 0.05 and outliers in mouse analyses were defined a
priori as greater than 2 SD from the mean. A Holm P-
Table 2. Human EEG cohort.
Diagnosis (n) Control cases (8) DLB cases (6)
Age (mean  SD) 68.4  3.0 73.0  6.6
Gender (M/F) 5/3 4/2
Education (years) (mean  SD) 17.3  3.0 19.0  7.5
Handedness (R/L) 4/4 6/0
EEG, electroencephalography; DLB, Dementia with Lewy bodies; R,
right-handed; L, left-handed.
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value correction was used for multiple comparisons, as
specified in the figure legends.
Results
To detect changes in spectral power distribution in DLB
patients across a wide frequency range, we recorded EEGs
with a high sampling frequency in human subjects
(Table 2) while they were awake but had their eyes
closed. Average spectral power analysis revealed the aver-
age dominant peak frequency to be in the alpha range
(8–12 Hz) in control subjects and in the theta range
(4–8 Hz) in DLB subjects (Fig. 2A), consistent with pre-
vious findings.2,3 Typical EEG analysis breaks spectral
power into frequency bands, but this provides a relatively
poor overall view of spectral power alterations. This is
especially true in DLB, in which the relative power of
many frequency bands is altered.2,3 Therefore, we ana-
lyzed the CDF of spectral power, which provides a con-
tinuous picture of the spectral power changes from 0 to
100 Hz. DLB patients showed a marked left shift in the
spectral power distribution toward slower frequencies as
compared to controls (Fig. 2B). Although DLB subjects
had more variable total power than controls (P = 0.0006,
F test), total power was not different between the groups,
indicating that their altered power distribution cannot be
attributed to a change in total power.
To assess whether neuronal accumulation of SYN could
causally contribute to these network abnormalities, we
recorded EEGs from 4- to 8-month-old transgenic mice
in which the Thy-1 promoter directs expression of human
wild-type SYN in neurons.12,18 At this age, these mice are
cognitively impaired and show abnormal neuronal SYN
accumulation in the hippocampus and cortex.12,13 EEG
and video recordings were obtained while mice were rest-
ing in a state of quiet wakefulness. Similar to humans
with DLB, SYN mice showed a slowing in the dominant
resting rhythm and a marked left shift in the spectral
power distribution (Fig. 2C–E). This shift consisted of an
increase in delta power and a decrease in the power of
theta and higher frequency bands (Fig. 2C and E). Total
spectral power was comparable in NTG and SYN mice,
indicating that the power shift in SYN mice reflects
primarily a change in power distribution.
Unexpectedly, EEGs recorded from SYN mice also
revealed epileptiform spikes, multi-spike complexes, and
seizures (Fig. 3A–E). During the first 24 h of recording,
28.6% (8/28) of SYN mice and 0% (0/12) of NTG
controls had at least one seizure. The seizures we
observed in SYN mice were of two types. The first,
more common type (Fig. 3D) had a typical electro-
graphic seizure pattern and was usually accompanied by
forelimb clonus, abnormal tonic posture, and tail exten-
sion. These seizures were typically of moderate intensity
and rarely caused only behavioral arrest or escalated into
full running/jumping activity. The second type of seizure
(Fig. 3E), which we refer to as a myoclonic burst sei-
zure, consisted of periodic, large amplitude spikes or
multi-spike complexes and was accompanied by myoclo-
nic jerks typically involving the neck, shoulder, and fore-
limb. Myoclonic burst seizures did not usually evolve
into other types of seizures. Both types of seizures sym-
metrically involved both hemispheres. During a 24-h
recording session, most SYN mice with seizures demon-
strated only one or the other of these seizure types.
Both seizure types were also observed in mice that had
not undergone surgical or pharmacological manipulation
(data not shown).
We next looked for immunohistochemical changes in
the hippocampus that are typically caused by epileptic
activity.23–26 Compared with NTG controls, SYN mice had
reduced levels of calbindin in granule cells of the dentate
gyrus and the stratum radiatum of CA1 (Fig. 3F–H),
increased or ectopic expression of NPY in the molecular
layer of the dentate gyrus and the mossy fiber pathway
(Fig. 3F, I, and J), and fewer cfos-positive granule cells
(Fig. 3F and K). All these changes were seen in the presence
of recurrent seizure activity.24,25,27 SYN accumulation in
the hippocampus of SYN mice was inversely correlated
with levels of calbindin in dentate granule cells (Fig. 4). An
independent line of transgenic mice expressing SYN under
the PDGF promoter showed similar hippocampal
alterations (Fig. 5), making it unlikely that the abnormali-
ties we detected in SYN mice were caused by insertional
Figure 3. Epilepsy and related immunohistochemical alterations in SYN mice. (A–E) Representative EEG traces showing normal activity in a NTG
mouse (A) and frequent epileptiform spikes (arrowheads in B), multispike complexes (arrowheads in C), a seizure (D) accompanied by tail
extension and bilateral forelimb clonus (not shown), and a myoclonic burst seizure (E) in SYN mice. (F–K) Hippocampal changes in neuronal
activity-dependent proteins in SYN mice (n = 11–15 mice per genotype, age 5–7 months). Hippocampal sections from SYN and NTG mice were
immunostained for calbindin, NPY, or cfos and analyzed by densitometry (calbindin/NPY) and cell counting (cfos). (F) Representative images from
NTG and SYN mice. Scale bars: 0.5 mm (Calbindin/NPY) and 0.1 mm (cfos). Calbindin was measured in the molecular layer of the dentate gyrus
(G) and the stratum radiatum of CA1 (H), NPY in the mossy fibers (I) and the molecular layer (J), and cfos-positive cells in the granular layer (K).
*P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test). Quantitative values represent mean  SEM. SYN, a-synuclein; EEG,
electroencephalography; NTG, nontransgenic; NPY, neuropeptide Y; LPC, left parietal cortex; RPC, right parietal cortex; DG, dentate gyrus; OD,
optical density; RU, relative units.
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mutagenesis or other positional effects resulting from the
integration of the transgene into the genome.
To determine whether epileptic activity is sufficient to
cause a left shift in spectral power, we examined trans-
genic mice with neuronal expression of mutant hAPP
from line J20.19,26,28,29 These mice exhibit robust epileptic
activity and have dysregulated gamma activity.22,26 A
side-by-side comparison of EEG recordings in SYN and
hAPP mice matched for age and background strain
revealed clear differences in resting spectral power. SYN
mice again showed a left shift in spectral power compared
to NTG littermates, whereas hAPP mice and NTG litter-
mates showed a similar resting spectral power distribution
(Fig. 6A). Therefore, neuronal expression of transgene-
derived proteins and epileptic activity are not sufficient to
cause a left shift in spectral power during a resting EEG.
We next assessed more directly if epileptic activity con-
tributed to spectral changes in SYN mice. Acute injection
of phenobarbital (5 mg/kg, i.p.) decreased interictal
epileptiform events by 55% but did not affect spectral
power in SYN mice (Fig. 6B and C). Similarly, ablation
of the microtubule-associated protein tau, which has been
shown to reduce epileptic activity in a variety of seizure
models,28,30–34 tended to reduce interictal events by
roughly 50% but, if anything, tended to slightly increase
the left shift in spectral power in SYN mice (Fig. 6D and
E). Tau ablation also reduced some seizure-related bio-
Figure 4. Hippocampal SYN accumulation correlates with calbindin
reduction in dentate granule cells. Hippocampal sections from SYN
and NTG mice (n = 5–6 mice per genotype, age 5–6 months) were
immunostained for calbindin and analyzed by densitometry. Levels of
total and phosphorylated SYN in contralateral hippocampi were
determined by Western blot analysis and normalized to tubulin as a
loading control. Calbindin levels correlated inversely with levels of
total SYN (A, P = 0.0025, R2 = 0.92) and phosphorylated SYN (B,
P = 0.0032, R2 = 0.91) in SYN mice (black squares). Average
calbindin levels in NTG mice (open circles) were arbitrarily defined as
100%. Solid lines are the product of a linear regression analysis. SYN,
a-synuclein; NTG, nontransgenic; pSYN, phosphorylated SYN.
Figure 5. Neuronal expression of SYN directed by the PDGF promoter
also causes hippocampal changes in activity-dependent proteins in an
independent line of transgenic mice. (A–D) Hippocampal sections from
PDGF-SYN mice and NTG controls were immunostained for calbindin or
NPY and analyzed by densitometry (n = 8 mice per genotype).
Calbindin was measured in the molecular layer of the dentate gyrus (A)
and the stratum radiatum of CA1 (B), and NPY in the mossy fibers (C)
and the molecular layer (D) of the dentate gyrus. **P < 0.01,
***P < 0.001 (Student’s t-test). The age of mice ranged from 3 to
17 months and was not significantly different between NTG and SYN
mice (mean  SEM: 9.1  1.39 for NTG and 10.4  1.75 for SYN
mice, P = 0.57 by Student’s t-test). Bars represent means  SEM. SYN,
a-synuclein; NTG, nontransgenic; NPY, neuropeptide Y; DG, dentate
gyrus; OD, optical density; RU, relative units.
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chemical alterations in the hippocampus of SYN mice
(Fig. 6F–H), although alterations in granule cell calbindin
and mossy fiber NPY were not affected (data not shown).
Thus, neither acute nor chronic reduction of epileptiform
activity altered spectral power in SYN mice, suggesting
that epileptiform activity may not be a critical cause or
mediator of the left shift in spectral power.
Inhibiting cholinergic signaling in rats caused a left
shift in spectral power similar to the shift we observed in
untreated SYN mice.35,36 We therefore wondered whether
increasing cholinergic neurotransmission by inhibiting
acetylcholinesterase might reverse spectral changes in SYN
mice. Donepezil, an acetylcholinesterase inhibitor, was
injected daily for 14 days at 1 mg/kg (i.p.), a dose that
yields plasma drug levels similar to those observed in
human clinical trials.37 EEG recordings were performed
just before the treatment began (baseline), after the last
injection, and after a washout period of 7 days. Donepezil
did not reverse the spectral power shift in SYN mice,
although there was a trend toward a right-shift in the
power distribution in both NTG and SYN mice (Fig. 6I).
Although oscillatory abnormalities in DLB patients
have been well documented,2,3 few studies have examined
neural network excitability in these patients. One small
study raised the possibility of an increased incidence of
Figure 6. Modulation of epileptic activity does not shift spectral
power. (A) SYN mice (black solid line), hAPP-J20 mice (red dotted
line) and their combined NTG littermate controls (black dashed line)
were compared by EEG (n = 3–7 mice per group, age 4–5 months).
SYN mice showed a left shift, whereas hAPP mice did not (NTG
versus SYN P < 0.0003, hAPP versus SYN P < 0.0003, NTG versus
hAPP P = 0.06, by Kolmogrov–Smirnov test with Holm correction). (B
and C) Acute injection of phenobarbital (5 mg/kg, i.p.) reduced
interictal spike activity (B) but did not alter the spectral power
distribution (C, P = 0.70 by Kolmogrov–Smirnov test) in SYN mice
(preinjection, black solid line; postinjection, red dotted line; n = 6–10
mice, age 3–7 months). (D and E) Genetic ablation of tau caused a
trend toward reduced epileptic activity (D, P = 0.17 by Tukey test
multiply adjusted P value) and a trend toward an increased left shift
in spectral power distribution (E, P = 0.09 by Kolmogrov–Smirnov
test) in SYN mice (Tau+/+, black solid line; Tau/, red dotted line;
n = 6–7 mice per genotype, age 4–7 months). Dotted line in D
represents the average level in NTG controls. (F–H) Hippocampal
sections from Tau+/+, Tau/, SYN/Tau+/+ and SYN/Tau/ littermates
(No SYN, white bars; SYN, black bars; n = 10–13 mice per genotype,
age 4–5 months) were immunostained for calbindin, NPY, or cfos and
analyzed by densitometry (calbindin/NPY) or cell counting (cfos).
Calbindin was measured in the stratum radiatum of CA1 (F), NPY in
the molecular layer (G), and cfos-positive cells in the granular layer
(H). (I) Donepezil (1 mg/kg, i.p.) was injected once daily for 14 days in
SYN mice and NTG controls (n = 3–6 mice per genotype and
treatment, age 4–6 months). Spectral power distribution in NTG and
SYN mice is shown for the last day of donepezil treatment (NTG with
donepezil, blue dashed line; SYN with donepezil, red solid line) and
after 7 days of drug washout (NTG, black dashed line; SYN, black
solid line). Kolmogorov–Smirnov test with Holm correction revealed a
genotype effect during (P = 0.002) and after (P < 0.005) donepezil
treatment, but no effects of treatment in SYN mice (P = 0.84) or NTG
controls (P = 0.90). 0–40 Hz zoom shown for clarity. (A, C, E, and I)
Quantitative values are means. (B, D, and F–H) *P < 0.05, **P < 0.01
versus NTG or as indicated by brackets (Tukey test), ***P < 0.001
versus preinjection baseline (one-sample t-test). Bars represent
means  SEM. SYN, a-synuclein; hAPP, human amyloid precursor
protein; NTG, nontransgenic; EEG, electroencephalography; NPY,
neuropeptide Y; ML, molecular layer; OD, optical density; RU, relative
units.
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seizures in DLB patients38 and a second group docu-
mented cortical myoclonus, a form of cortical hyperex-
citability, in DLB patients.39 To look for biochemical
evidence suggestive of aberrant network excitability in
these patients, we examined calbindin levels in their den-
tate gyrus. Patients with temporal lobe epilepsy or AD
show reduced calbindin levels in dentate granule cells,
and such calbindin reductions are thought to reflect aber-
rant hippocampal excitability.40–42 Using qRT-PCR, we
determined calbindin mRNA levels in the dentate gyrus
obtained postmortem from humans with neocortical DLB
pathology and low or high levels of AD pathology
(Table 1). Dentate gyrus samples from AD cases and from
people without neurodegenerative disease were used as
positive and negative controls, respectively.41,42 DLB cases
without AD pathology showed markedly reduced levels of
calbindin mRNA in the dentate gyrus, similar in extent to
reductions seen in AD (Fig. 7). The most striking loss of
calbindin mRNA was observed in DLB cases with a high
level of AD pathology, although calbindin mRNA levels
in these cases were not significantly different from those
in cases with AD or DLB pathology alone (Fig. 7).
To further assess whether aberrant network excitability
may contribute to SYN-related dementia, we reviewed the
charts of patients who were seen at the UCSF Memory
and Aging Center between 2007 and 2012 and who met
research criteria for DLB1 (Table 3). We searched the
charts for myoclonus and seizure disorders, both of which
are thought to result from aberrant network excitabil-
ity.39,43,44
Myoclonus was noted in 21.7% (34/157) of patients
with clinically diagnosed DLB, consistent with the
estimated prevalence of myoclonus in pathologically con-
firmed cases of diffuse Lewy body disease.45 Myoclonus
and male gender were associated with a lower age of
onset of cognitive impairment (65.9  8.22 with myoclo-
nus, 70.74  8.79 without myoclonus; 67.9  8.81 male,
72.4  8.32 female) in a mixed effects linear model
(Table 3). The incidence of myoclonus in DLB was
markedly higher than that in an age-matched reference
population (Table 4 and ref. 46).
Roughly 2.5% (4/157) of patients with DLB were noted
to have a seizure disorder. An additional 7.6% (12/157)
of DLB patients were suspected to have a seizure disorder
but were not formally diagnosed. The FUS in epileptic
DLB patients typically occurred near the time of dementia
Figure 7. Reduction of calbindin mRNA levels in the dentate gyrus of
humans with DLB and/or AD pathology. Calbindin mRNA levels in
postmortem tissue samples were quantified by qRT-PCR and
normalized to 18S RNA as a loading control. n = 3 controls without
neurodegenerative disease, n = 5–7 cases per disease group. In cases
with DLB plus high AD pathology (DLB + AD), there was an
interaction between Alzheimer’s and Lewy body pathology (P < 0.001
by two-way ANOVA). ***P < 0.001 versus control (Tukey test). Values
are means  SEM. DLB, Dementia with Lewy bodies; AD, Alzheimer’s
disease; ANOVA, analysis of variance.
Table 3. Associations between DLB patient characteristics and age at
onset of cognitive decline.
Characteristic DLB (157)
Age at
onset
model
(P-value)
Sex (M/F) 93/64 0.003
Education (years) (mean  SD)1 15.5  4.0 0.41
Handedness (R/L/A) 139/14/4 0.97
Patients with fluctuations (%) 100 (63.7%) 0.67
Patients with a seizure disorder (%) 4 (2.5%) 0.48
Patients with myoclonus (%)2 34 (21.7%) 0.006
DLB, dementia with Lewy bodies; R, right-handed; L, left-handed; A,
ambidextrous. Italics indicate statistical significance.
1One DLB patient was missing education information.
2One DLB patient had both myoclonus and a seizure disorder.
Table 4. Incidence of seizures and myoclonus in humans with
dementia with Lewy bodies by age.
Clinical sign Age1 n Population Incidence2
Relative rate
(95% CI)
Seizures 70–79 1 71 234.7 1.5
(0.2–11.2)3
80+ 2 36 925.9 5.4
(1.3–22.8)3
Myoclonus 50–69 7 41 2845.5 1485.5
(434.9–5074.5)4
70+ 11 102 1797.4 248.3
(96.2–640.4)4
1Age-ranges dictated by epidemiological studies in control popula-
tions.
2Per 100,000 person-years.
3Compared to Forsgren et al.47
4Compared to Caviness et al.46.
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diagnosis (median:1 year relative to diagnosis, range:1 to
+1), but was not related to the age of onset of cognitive
impairment (75.3  6.50 with epilepsy vs. 69.6  8.89
without epilepsy). The incidence of new-onset, unpro-
voked seizures in our DLB population tended to be
higher than that of an age-matched general population
(Table 4 and ref. 47). However, the magnitude of the
effect was difficult to evaluate due to the small number of
events during the incidence study period.
Autopsies were obtained in 12 DLB patients and
revealed a high diagnostic accuracy for neocortical Lewy
bodies: 11 of 12 cases were confirmed pathologically; one
case showed only AD pathology. Based on McKeith
criteria,1 there was a high likelihood that Lewy body
pathology accounted for dementia in six cases and an
intermediate likelihood for the remaining five cases,
which had high levels of concomitant AD pathology. Four
DLB patients with myoclonus that came to autopsy all
had neocortical Lewy bodies; two of them also had
numerous plaques and tangles, one had a high level of
plaques without tangles, and one had no appreciable AD
pathology. However, the low number of autopsies pre-
cluded us from reliably assessing the relative contributions
of DLB and AD pathology to clinical features.
Discussion
Our study demonstrates that neuronal overexpression of
wild-type human SYN causes a left shift in spectral power
in transgenic mice that closely resembles spectral alterations
in humans with DLB. A similar shift in spectral power was
observed in SYN mice during both wakefulness and sleep.48
These findings support the hypothesis that accumulation of
SYN, which characterizes DLB pathologically, is at least
partly responsible for network dysfunction in DLB patients.
We further obtained evidence for aberrant network
excitability in SYN mice and in humans with DLB. Our
study also suggests that the mechanisms by which SYN
causes these two types of network dysfunction are at least
partly distinct, although it should be noted that the
interventions used in our study achieved only a partial
suppression of epileptiform activity in SYN mice.
The most direct evidence for aberrant network
excitability in SYN mice consisted of interictal spikes and
intermittent seizures that were associated with typical
alterations on EEG and in motor behavior. These func-
tional changes were accompanied by immunohistochemi-
cal alterations in the hippocampus that typically result
from aberrant network excitability, including reduced cal-
bindin levels. In transgenic mice, hippocampal SYN levels
correlated with calbindin reduction in the dentate gyrus,
suggesting that aberrant network excitability is directly
related to accumulation of SYN. We suspect that the
aberrant network excitability in SYN mice is caused by
small soluble assemblies of SYN, which are present in
SYN mice at a young age,49 rather than by larger, insol-
uble SYN aggregates. Reduced calbindin expression in the
dentate gyrus was also detected in DLB patients. Our
interpretation that this biochemical alteration also reflects
aberrant network excitability in humans is supported by
the clinical evidence of aberrant network excitability we
found in our chart review. Notably, it is likely that cal-
bindin depletion in the hippocampus is a more sensitive
indicator of aberrant network excitability then routine
scalp EEG, which can easily miss intermittent epileptiform
events and is notoriously insensitive to epileptic activity
in deeper brain regions such as the hippocampus.50,51
A limitation of our mouse experiments is that all
spectral analyses were performed on EEG recordings
obtained over the parietal cortex of resting mice. We
focused on this brain region because it shows a spectral
shift in DLB (Fig. 2 and ref. 3), and on resting behavior
in mice to mimic human EEG conditions. Recordings
from other brain regions and task-related spectral analyses
may provide additional insights into neuronal network
dysfunction. For example, EEG recordings over the fron-
tal cortex might be more suitable for assessing potential
contributions of cholinergic deficits to spectral alterations
in SYN mice, and analysis of individual EEG recordings
in actively exploring mice could help reveal the kind of
dysregulation of gamma oscillations we observed in hAPP
mice.22 Additionally, our EEG recordings were limited to
one transgenic line. The relevance of our neurophysiologi-
cal findings to that of other transgenic mouse models of
DLB warrants further investigation.
While overexpression of human SYN caused obvious sei-
zure activity in transgenic mice, the more chronic accumu-
lation of endogenous SYN in DLB patients may primarily
cause more subtle signs of aberrant network excitability
such as myoclonus. Myoclonus in DLB and PD consists of
a sudden brief jerk that is accompanied by a sharp transient
in the contralateral sensorimotor cortex on EEG.39,43 This
type of myoclonus, called cortical myoclonus, may be
caused by aberrant cortical excitability39,43,44 and has been
successfully treated with anti-epileptic drugs.52–54 In our
study, myoclonus was associated with an earlier age of
onset of cognitive impairment, raising the possibility that
aberrant network excitability may contribute to cognitive
dysfunction in DLB. Interestingly, levels of SYN in the sen-
sorimotor cortex were higher in PD patients with myoclo-
nus than in those without.55 Increased cortical SYN
pathology may also explain why myoclonus is more fre-
quent, and is thought to be more severe, in DLB patients
than in PD patients.39,45
In patients with early AD and a seizure disorder, a
substantial proportion of the seizure activity was noncon-
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vulsive and could have easily been missed on routine
exams.51 This caveat may also apply to DLB. Indeed,
symptoms similar to those associated with nonconvulsive
seizures, such as staring spells and disorganized speech,
can occur during the episodes of fluctuating conscious-
ness often seen in DLB patients. These episodes make it
particularly difficult to distinguish between epileptic and
nonepileptic symptoms. Among the DLB cases we
reviewed, one of four patients with a diagnosed seizure
disorder had only nonconvulsive seizures and another 10
patients were suspected to have this type of seizure.
Although we compared the incidence of myoclonus and
seizures to the best reference populations we could find
in the literature,56 our relative rate calculations may be
confounded by differences in racial and age distributions
in the San Francisco Bay Area versus Rochester,
Minnesota and Umea, Sweden.46,47 A prospective clinical
study is needed to more accurately determine the
incidence of seizures and myoclonus in DLB patients.
We previously identified co-pathogenic interactions
between Ab and SYN in hAPP/SYN doubly transgenic
mice57 that may be relevant to the frequent co-occurrence
of DLB and AD pathology.58–60 Because clinical assess-
ment alone cannot reliably detect the co-occurrence of
these pathologies,59 an obvious limitation of our study is
the lack of autopsy confirmation of most cases we
analyzed by chart review or EEG. However, spectral slow-
ing has been documented in autopsy-confirmed cases of
DLB61 and was confirmed here with a different approach
to spectral analysis. Furthermore, the reduction in
calbindin mRNA was identified in cases with pathologi-
cally confirmed DLB, AD, or both and suggests that SYN
pathology is sufficient to cause aberrant network
excitability. Again, a prospective study of DLB with imag-
ing for AD pathology and/or autopsy confirmation is
needed to further test this hypothesis.
In conclusion, our analysis of experimental models
clearly demonstrates that SYN accumulation causes both
a shift in the EEG spectrum toward slower brain oscil-
lations as well as aberrant network excitability. We also
obtained evidence suggesting that the mechanisms
underlying these network effects may be at least partly
distinct. While treatments targeting SYN should block
both types of network dysfunction, drugs with different
modes of action may have to be combined in order to
block divergent branches of the SYN-induced patho-
genic cascade further downstream. Recent evidence sug-
gests that the hyperactivation of specific neural
networks may contribute to cognitive deficits in early
stages of AD and that specific anti-epileptic drugs may
be able to reverse synaptic, network, and cognitive dys-
function in this condition and related models.29,51,62
Our study raises the possibility that network hyperex-
citability may also contribute to cognitive or behavioral
alterations in DLB.
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